Brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to report sales of $2.65 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Spero Therapeutics’ earnings. The lowest sales estimate is $2.30 million and the highest is $3.00 million. Spero Therapeutics posted sales of $5.15 million during the […]
Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 1,650,000 shares, a decline of 55.3% from the April 30th total of 3,690,000 shares. Based on an average daily volume of 634,900 shares, the […]
Wall Street analysts expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to announce earnings of ($0.77) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.56). Spero Therapeutics posted earnings per share of ($0.63) during the […]
Spero Therapeutics (NASDAQ:SPRO – Get Rating) announced its quarterly earnings data on Monday. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.14), MarketWatch Earnings reports. Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same period in the […]
Spero Therapeutics (NASDAQ:SPRO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. […]